As outlined in the ‘Introduction’, use of multiple radiopharmaceuticals for FDG, tau and amyloid-PET is an expensive and resource-intensive prospect, now emerging as an area of research and clinical need with recent FDA accelerated approval of Alzheimer’s disease-modifying therapy91 and the potential for additional targeted therapies in the future. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.